08:00 , Jan 2, 2012 |  BioCentury  |  Finance

Small-fry squashed

Among last year's best-performing large cap biotechs were an acquiree and an acquirer: HCV play Pharmasset Inc. and Valeant Pharmaceuticals International Inc. Other big cap stocks also did well overall, while investors abandoned their small-...
08:00 , Dec 5, 2011 |  BC Week In Review  |  Clinical News

Zevalin ibritumomab tiuxetan regulatory update

FDA approved a post-approval supplement from Spectrum to remove the requirement for Zevalin indium-111 pre-treatment imaging evaluation prior to treatment with Spectrum's Zevalin ibritumomab tiuxetan. Spectrum said removing the bioscan requirement would reduce treatment visits...
07:00 , Mar 28, 2011 |  BC Week In Review  |  Clinical News

Zevalin ibritumomab tiuxetan regulatory update

FDA accepted for review a post-approval supplement from Spectrum for Zevalin ibritumomab tiuxetan to remove the requirement for Zevalin indium-111 pre-treatment imaging evaluation. The PDUFA date is Nov. 20. Spectrum said removing the bioscan requirement...
08:00 , Jan 31, 2011 |  BC Week In Review  |  Clinical News

Zevalin ibritumomab tiuxetan regulatory update

Spectrum submitted a post-approval supplement to FDA for Zevalin ibritumomab tiuxetan to remove the requirement for Zevalin indium-111 pre-treatment imaging evaluation. Spectrum said removing the bioscan requirement would reduce treatment visits and costs. Zevalin is...
07:00 , May 16, 2005 |  BioCentury  |  Finance

Copenhagen performance

Copenhagen performance A price-weighted index consisting of five biotechs on the Copenhagen Stock Exchange - Bavarian Nordic, Bioscan, Genmab, NeuroSearch and Pharmexa - was up 39% over the past 12 months. In comparison, the BioCentury...
07:00 , Jul 1, 2002 |  BC Week In Review  |  Company News

Bioscan board of directors update

Bioscan A/S (CSE:BIOS), Odense, Denmark   Business: Agbio/Veterinary/Environmental   Resigned: Niels Andersen, as chairman; Arne Knudsen; Per Christiansen; and Gert Petersen  ...
08:00 , Dec 3, 2001 |  BC Week In Review  |  Company News

Bioscan, E3 International Corp. deal

BIOS said negotiations with E3 concerning a U.S. licensing agreement for BIOS’s Biorek technology have not yet been completed. BIOS expects the deal to be in place in December, with a license payment of $3...
07:00 , Sep 24, 2001 |  BioCentury  |  Finance

Ebb & Flow

Amid the sucking sound of the WTC market meltdown, Actelion (SWX:ATLN) was one of the few companies rewarded for key milestones last week (see Cover Story). The stock closed the week up CHF3 to CHF41...